Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PMCB Stock Forecast 2025-2026
$1.22
Current Price
$8.37M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PMCB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PMCB Price Momentum
+8.0%
1 Week Change
-7.6%
1 Month Change
-42.2%
1 Year Change
-25.6%
Year-to-Date Change
-49.6%
From 52W High of $2.42
+18.4%
From 52W Low of $1.03
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching PharmaCyte (PMCB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PMCB and similar high-potential opportunities.
Latest PMCB Stock Price Targets & Analyst Predictions
PMCB has shown a year-to-date change of -25.6% and a 1-year change of -42.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PMCB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PMCB Analyst Ratings
0
Buy
0
Hold
0
Sell
PMCB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.22
Latest PMCB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PMCB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 8, 2021 | HC Wainwright & Co. | Edward White | Neutral | Initiates | $0.00 |
Pharmacyte Biotech Inc. (PMCB) Competitors
The following stocks are similar to PharmaCyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pharmacyte Biotech Inc. (PMCB) Financial Data
Pharmacyte Biotech Inc. has a market capitalization of $8.37M with a P/E ratio of 0.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +42.9%.
Valuation Metrics
Market Cap
$8.37M
Enterprise Value
$-8,382,379
P/E Ratio
0.9x
PEG Ratio
-3.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+200.1%
Current Ratio
14.2x
Debt/Equity
0.0x
ROE
+42.9%
ROA
-4.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pharmacyte Biotech Inc. (PMCB) Business Model
About Pharmacyte Biotech Inc.
What They Do
Develops cellular therapies for cancer and diabetes.
Business Model
The company focuses on developing and commercializing innovative cellular therapies, primarily utilizing its proprietary Cell-in-a-Box technology for targeted chemotherapy delivery. It aims to generate revenue through the successful development and commercialization of these therapies, addressing unmet medical needs in cancer and diabetes management.
Additional Information
Pharmacyte Biotech Inc. operates in the rapidly growing biotech sector and collaborates with researchers and medical professionals to enhance healthcare outcomes. Its technology is designed to improve treatment efficacy while reducing side effects, positioning the company as a potential leader in precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2
CEO
Mr. Joshua N. Silverman
Country
United States
IPO Year
2003
Website
pharmacyte.comPharmacyte Biotech Inc. (PMCB) Latest News & Analysis
Latest News
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
11 months ago
Quick Summary
PharmaCyte Biotech (PMCB) has invested $7 million in MyMD Pharmaceuticals (MYMD), which is advancing its MYMD-1 product for sarcopenia following positive Phase 2 trial results.
Why It Matters
PharmaCyte's $7 million investment in MyMD, coupled with positive Phase 2 trial results for MYMD-1, could enhance MyMD's growth prospects and boost investor sentiment in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
MyMD Pharmaceuticals Secures Strategic Investments
11 months ago
Quick Summary
MyMD Pharmaceuticals has secured $7 million in commitments from two private placements, led by PharmaCyte Biotech, to support its development of therapies for age-related and autoimmune diseases.
Why It Matters
MyMD Pharmaceuticals' $7 million funding from a strategic investor indicates strong confidence in its growth potential, which could enhance its valuation and attract further investment.
Source: Business Wire
Market Sentiment:
Neutral
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
1 year ago
Quick Summary
PharmaCyte Biotech (Nasdaq: PMCB) has invested $5 million in Femasys (Nasdaq: FEMY), a biomedical company addressing unmet needs for women's health with innovative solutions.
Why It Matters
PharmaCyte's $5 million investment in Femasys signals confidence in its growth potential and the women's health sector, potentially impacting share prices and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaCyte Biotech (Nasdaq: PMCB) is seeking a meeting with the FDA to discuss the development of its Cell-in-a-Box technology, anticipated in Q1 2024.
Why It Matters
PharmaCyte's FDA meeting request signals potential advancements in its Cell-in-a-Box technology, which may impact its development timeline and future market value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaCyte Biotech, Inc. completed its tender offer to buy back 7.75 million shares at $3.25 each. The offer expired on June 9, 2023, and was funded by the company's cash reserves.
Why It Matters
PharmaCyte's tender offer indicates management's confidence in the stock's value and aims to reduce share count, potentially increasing earnings per share and appealing to investors seeking value.
Source: Business Wire
Market Sentiment:
Neutral
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
1 year ago
Quick Summary
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) has launched a cash tender offer for up to 7.75 million shares at $3.25 each and completed a private placement raising about $35 million.
Why It Matters
PharmaCyte's cash tender offer and successful financing indicate a strong cash position and potential for shareholder value enhancement, which could positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PMCB Stock
What is Pharmacyte Biotech Inc.'s (PMCB) stock forecast for 2025?
Analyst forecasts for Pharmacyte Biotech Inc. (PMCB) are not currently available. The stock is trading at $1.22.
Is PMCB stock a good investment in 2025?
Analyst ratings for PMCB are not currently available. The stock is currently trading at $1.22. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PMCB stock?
Price predictions from Wall Street analysts for PMCB are not currently available. The stock is trading at $1.22.
What is Pharmacyte Biotech Inc.'s business model?
The company focuses on developing and commercializing innovative cellular therapies, primarily utilizing its proprietary Cell-in-a-Box technology for targeted chemotherapy delivery. It aims to generate revenue through the successful development and commercialization of these therapies, addressing unmet medical needs in cancer and diabetes management.
What is the highest forecasted price for PMCB Pharmacyte Biotech Inc.?
Price targets from Wall Street analysts for PMCB are not currently available. The stock is trading at $1.22.
What is the lowest forecasted price for PMCB Pharmacyte Biotech Inc.?
Price targets from Wall Street analysts for PMCB are not currently available. The stock is trading at $1.22.
What is the overall PMCB consensus from analysts for Pharmacyte Biotech Inc.?
Analyst ratings for PMCB are not currently available. The stock is trading at $1.22.
How accurate are PMCB stock price projections?
Stock price projections, including those for Pharmacyte Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:27 PM UTC